Vivreon Biosciences is a pioneering brand dedicated to revolutionizing the treatment of chronic inflammatory diseases. By leveraging their therapeutic discovery platform, they are creating transformative pharmaceutical companies that offer groundbreaking solutions. Their candidate therapies target a central regulator of immune function, effectively defending healthy tissue.

In the field of neurodegenerative diseases, Vivreon Neurosciences focuses on combating neuroinflammation, a key contributor to disease progression. Their research has led to the discovery of potent lead series of candidate neuroprotective therapeutic drugs. These drugs not only enter the brain but also interfere with chronic neurodegenerative microgliosis, addressing the root cause of inflammation.

This breakthrough has the potential to significantly improve the lives of individuals suffering from these debilitating conditions. In addition, Vivreon Gastrosciences is dedicated to combatting inflammatory bowel diseases (IBD). With the number of affected individuals increasing each year, the need for improved therapies is more pressing than ever.

Vivreon Gastrosciences aims to develop an alternative approach to completely and specifically suppress gastrointestinal inflammation, providing hope for the over 1 million people in the United States alone who do not respond to current therapies. Vivreon Biosciences is committed to pushing the boundaries of medical advancements and developing innovative treatments that make a positive impact on patients' lives